Form 4: Viking Therapeutics COO Reports Stock Award Vesting and Tax Withholding

Marianna Mancini, COO of Viking Therapeutics, reports the vesting of performance-based restricted stock units and subsequent tax withholding.

Summary

• On March 1, 2024, Marianna Mancini, Chief Operating Officer of Viking Therapeutics, had 31,667 shares of common stock vest as part of a performance restricted stock unit award granted on January 3, 2023.
• This vesting occurred because 33.33% of the award vested upon achievement of a non-financial performance goal.
• Also on March 1, 2024, 16,958 shares were withheld by Viking Therapeutics to satisfy tax obligations related to the vesting of these restricted stock units at a price of $85.22.
• Following these transactions, Mancini directly owns 348,508 shares of Viking Therapeutics common stock.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing detailing stock transactions by a company executive. It doesn't contain overtly positive or negative information, but the vesting of performance-based stock suggests the company is meeting its goals.

Positives

• The vesting of performance-based restricted stock units suggests that Viking Therapeutics has achieved certain non-financial performance goals.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders. This filing indicates changes in the beneficial ownership of Viking Therapeutics' stock by its Chief Operating Officer.

Stakeholder Impact

• The vesting of stock options and restricted stock units can be seen as a positive sign by shareholders, as it aligns management's interests with the company's performance.

Key Dates